BeOne Medicines (NASDAQ:ONC) Director Sells $895,544.30 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Corazon (Corsee) Sanders sold 2,627 shares of the company’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total value of $895,544.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

BeOne Medicines Stock Performance

Shares of BeOne Medicines stock opened at $337.86 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $385.22. The firm has a market capitalization of $40.05 billion, a P/E ratio of 662.47 and a beta of 0.45. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $332.86 and a two-hundred day simple moving average of $301.43.

Institutional Trading of BeOne Medicines

A number of institutional investors and hedge funds have recently modified their holdings of ONC. Primecap Management Co. CA bought a new position in shares of BeOne Medicines during the second quarter valued at $1,231,720,000. Temasek Holdings Private Ltd bought a new stake in BeOne Medicines in the 2nd quarter worth about $244,603,000. Marshall Wace LLP purchased a new position in BeOne Medicines in the 2nd quarter worth about $113,190,000. Baird Financial Group Inc. bought a new position in BeOne Medicines during the 2nd quarter valued at about $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $73,347,000. Institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

ONC has been the topic of several research reports. Guggenheim boosted their price objective on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 3rd. Citizens Jmp raised their price objective on BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their target price on BeOne Medicines from $395.00 to $408.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $365.79.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.